UNITED THERAPEUTICS CORP (UTHR)
US91307C1027 - Common Stock
Taking everything into account, UTHR scores 7 out of 10 in our fundamental rating. UTHR was compared to 572 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making UTHR a very profitable company, without any liquidiy or solvency issues. UTHR is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make UTHR suitable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
UTHR had positive earnings in the past year.
In the past year UTHR had a positive cash flow from operations.
UTHR had positive earnings in 4 of the past 5 years.
Of the past 5 years UTHR 4 years had a positive operating cash flow.
1.2 Ratios
The Return On Assets of UTHR (15.60%) is better than 97.88% of its industry peers.
Looking at the Return On Equity, with a value of 18.21%, UTHR belongs to the top of the industry, outperforming 96.99% of the companies in the same industry.
UTHR has a better Return On Invested Capital (16.59%) than 97.52% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for UTHR is in line with the industry average of 13.83%.
The 3 year average ROIC (12.87%) for UTHR is below the current ROIC(16.59%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.6% | ||
| ROE | 18.21% | ||
| ROIC | 16.59% |
ROA(3y)11.66%
ROA(5y)8.69%
ROE(3y)14.55%
ROE(5y)11.01%
ROIC(3y)12.87%
ROIC(5y)12.67%
1.3 Margins
UTHR has a better Profit Margin (40.31%) than 98.58% of its industry peers.
In the last couple of years the Profit Margin of UTHR has grown nicely.
UTHR has a better Operating Margin (48.91%) than 99.82% of its industry peers.
UTHR's Operating Margin has been stable in the last couple of years.
UTHR has a better Gross Margin (88.94%) than 91.86% of its industry peers.
In the last couple of years the Gross Margin of UTHR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 48.91% | ||
| PM (TTM) | 40.31% | ||
| GM | 88.94% |
OM growth 3Y8.46%
OM growth 5Y0.63%
PM growth 3Y6.83%
PM growth 5Y3.17%
GM growth 3Y-1.38%
GM growth 5Y0.26%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), UTHR is creating some value.
UTHR has more shares outstanding than it did 1 year ago.
UTHR has more shares outstanding than it did 5 years ago.
UTHR has a better debt/assets ratio than last year.
2.2 Solvency
UTHR has an Altman-Z score of 12.46. This indicates that UTHR is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of UTHR (12.46) is better than 88.85% of its industry peers.
There is no outstanding debt for UTHR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.45 | ||
| Altman-Z | 12.46 |
ROIC/WACC1.53
WACC10.85%
2.3 Liquidity
UTHR has a Current Ratio of 4.58. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.58, UTHR is in line with its industry, outperforming 50.80% of the companies in the same industry.
UTHR has a Quick Ratio of 4.41. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
UTHR has a Quick ratio (4.41) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.58 | ||
| Quick Ratio | 4.41 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.45% over the past year.
UTHR shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.08% yearly.
The Revenue has grown by 25.04% in the past year. This is a very strong growth!
Measured over the past years, UTHR shows a small growth in Revenue. The Revenue has been growing by 7.41% on average per year.
EPS 1Y (TTM)25.45%
EPS 3Y19.66%
EPS 5Y8.08%
EPS Q2Q%18.77%
Revenue 1Y (TTM)25.04%
Revenue growth 3Y16.2%
Revenue growth 5Y7.41%
Sales Q2Q%22.89%
3.2 Future
Based on estimates for the next years, UTHR will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.20% on average per year.
Based on estimates for the next years, UTHR will show a quite strong growth in Revenue. The Revenue will grow by 10.71% on average per year.
EPS Next Y25.92%
EPS Next 2Y19.7%
EPS Next 3Y12.81%
EPS Next 5Y13.2%
Revenue Next Year25.67%
Revenue Next 2Y18%
Revenue Next 3Y14%
Revenue Next 5Y10.71%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 16.03, UTHR is valued correctly.
Based on the Price/Earnings ratio, UTHR is valued cheaply inside the industry as 96.28% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of UTHR to the average of the S&P500 Index (26.91), we can say UTHR is valued slightly cheaper.
A Price/Forward Earnings ratio of 12.84 indicates a correct valuation of UTHR.
UTHR's Price/Forward Earnings ratio is rather cheap when compared to the industry. UTHR is cheaper than 96.81% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.26, UTHR is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.03 | ||
| Fwd PE | 12.84 |
4.2 Price Multiples
UTHR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. UTHR is cheaper than 98.58% of the companies in the same industry.
UTHR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. UTHR is cheaper than 96.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.14 | ||
| EV/EBITDA | 8.2 |
4.3 Compensation for Growth
UTHR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
UTHR has an outstanding profitability rating, which may justify a higher PE ratio.
UTHR's earnings are expected to grow with 12.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.62
PEG (5Y)1.98
EPS Next 2Y19.7%
EPS Next 3Y12.81%
5. Dividend
5.1 Amount
No dividends for UTHR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
UNITED THERAPEUTICS CORP
NASDAQ:UTHR (1/10/2025, 8:00:01 PM)
After market: 364.97 0 (0%)364.97
-1.64 (-0.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.66%
Inst Owner Change-0.29%
Ins Owners1.77%
Ins Owner Change-2.72%
Market Cap16.29B
Analysts77.27
Price Target401.61 (10.04%)
Short Float %5.12%
Short Ratio6.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6.42%
Min EPS beat(2)-10.35%
Max EPS beat(2)-2.49%
EPS beat(4)2
Avg EPS beat(4)-0.92%
Min EPS beat(4)-10.35%
Max EPS beat(4)7.04%
EPS beat(8)5
Avg EPS beat(8)-2.72%
EPS beat(12)7
Avg EPS beat(12)-2.63%
EPS beat(16)8
Avg EPS beat(16)-8.19%
Revenue beat(2)2
Avg Revenue beat(2)1.46%
Min Revenue beat(2)1.3%
Max Revenue beat(2)1.61%
Revenue beat(4)4
Avg Revenue beat(4)3.51%
Min Revenue beat(4)1.3%
Max Revenue beat(4)6.48%
Revenue beat(8)6
Avg Revenue beat(8)2.1%
Revenue beat(12)8
Avg Revenue beat(12)1.8%
Revenue beat(16)12
Avg Revenue beat(16)2.86%
PT rev (1m)0%
PT rev (3m)7.13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.18%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)-1.05%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)6.62%
Revenue NY rev (1m)-0.1%
Revenue NY rev (3m)1.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.03 | ||
| Fwd PE | 12.84 | ||
| P/S | 5.91 | ||
| P/FCF | 18.14 | ||
| P/OCF | 14.33 | ||
| P/B | 2.67 | ||
| P/tB | 2.72 | ||
| EV/EBITDA | 8.2 |
EPS(TTM)22.77
EY6.24%
EPS(NY)28.43
Fwd EY7.79%
FCF(TTM)20.12
FCFY5.51%
OCF(TTM)25.46
OCFY6.98%
SpS61.74
BVpS136.67
TBVpS134.16
PEG (NY)0.62
PEG (5Y)1.98
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.6% | ||
| ROE | 18.21% | ||
| ROCE | 21.57% | ||
| ROIC | 16.59% | ||
| ROICexc | 35.46% | ||
| ROICexgc | 36.88% | ||
| OM | 48.91% | ||
| PM (TTM) | 40.31% | ||
| GM | 88.94% | ||
| FCFM | 32.58% |
ROA(3y)11.66%
ROA(5y)8.69%
ROE(3y)14.55%
ROE(5y)11.01%
ROIC(3y)12.87%
ROIC(5y)12.67%
ROICexc(3y)23.93%
ROICexc(5y)23.04%
ROICexgc(3y)24.48%
ROICexgc(5y)24.06%
ROCE(3y)16.74%
ROCE(5y)16.48%
ROICexcg growth 3Y12.25%
ROICexcg growth 5Y-6.96%
ROICexc growth 3Y13.45%
ROICexc growth 5Y-5.63%
OM growth 3Y8.46%
OM growth 5Y0.63%
PM growth 3Y6.83%
PM growth 5Y3.17%
GM growth 3Y-1.38%
GM growth 5Y0.26%
F-Score8
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.45 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 358.65% | ||
| Cap/Sales | 8.65% | ||
| Interest Coverage | 28.56 | ||
| Cash Conversion | 80.35% | ||
| Profit Quality | 80.84% | ||
| Current Ratio | 4.58 | ||
| Quick Ratio | 4.41 | ||
| Altman-Z | 12.46 |
F-Score8
WACC10.85%
ROIC/WACC1.53
Cap/Depr(3y)315.24%
Cap/Depr(5y)249.39%
Cap/Sales(3y)8.08%
Cap/Sales(5y)6.8%
Profit Quality(3y)89.17%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.45%
EPS 3Y19.66%
EPS 5Y8.08%
EPS Q2Q%18.77%
EPS Next Y25.92%
EPS Next 2Y19.7%
EPS Next 3Y12.81%
EPS Next 5Y13.2%
Revenue 1Y (TTM)25.04%
Revenue growth 3Y16.2%
Revenue growth 5Y7.41%
Sales Q2Q%22.89%
Revenue Next Year25.67%
Revenue Next 2Y18%
Revenue Next 3Y14%
Revenue Next 5Y10.71%
EBIT growth 1Y21.28%
EBIT growth 3Y26.04%
EBIT growth 5Y8.09%
EBIT Next Year27.64%
EBIT Next 3Y12.65%
EBIT Next 5Y1.04%
FCF growth 1Y32.27%
FCF growth 3Y2.39%
FCF growth 5Y4.71%
OCF growth 1Y33.89%
OCF growth 3Y8.98%
OCF growth 5Y4.67%